KG
VRTX icon

Kilter Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Kilter Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.6K Buy
122
+2
+2% +$886 0.02% 121
2026
Q1 		$53.6K Buy
120
+2
+2% +$933 0.02% 116
2025
Q4 		$53.5K Buy
118
+9
+8% +$3.88K 0.02% 110
2025
Q3 		$42.7K Sell
109
-3
-3% -$1.25K 0.02% 116
2025
Q2 		$49.9K Buy
+112
New +$51.6K 0.02% 92

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kilter Group's VRTX Position: Q2 2026 in Review

Kilter Group increased its Vertex Pharmaceuticals (VRTX) stake by 1.7% in Q2 2026, buying an estimated $886 and bringing the position to 122 shares worth $60.6K. The position accounts for 0.02% of the portfolio, ranked #121.

Kilter Group first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Kilter Group held 122 shares of Vertex Pharmaceuticals worth $60.6K as of Q2 2026.
  • Kilter Group bought 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
  • Vertex Pharmaceuticals made up 0.02% of Kilter Group's portfolio in Q2 2026, its #121 holding.
  • Kilter Group first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.